@ HNELHD CG 12 16 Sepsis Fact Sheet

Embed Size (px)

Citation preview

  • 7/30/2019 @ HNELHD CG 12 16 Sepsis Fact Sheet

    1/2

    FACT SHEETIssued: August 2012

    Immunology & Infectious DiseasesMicrobiology, Hunter Area Pathology

    ANTIBIOTICS

    Use one of the following options after assessing

    patient for a history of penicillin allergy:

    Piperacillin/tazobactam 4+0.5 g IV 8-hourly(preferred first line option)

    Ceftazidime 2g IV 8-hourly (option for patientwith non-immediate penicillin allergy)

    Vancomycin should NOT be used presumptively in

    febrile neutropenic patients unless the patient is in

    shock, is known to be colonised with methicillin-

    resistant Staphylococcus aureus (MRSA) or has

    clinical evidence of a catheter-related infection in a

    unit with a higher incidence of MRSA infection (ie.

    Calvary Mater Hospital).

    If any of these criteria are met, ADD vancomycin to

    the above regimen:

    Vancomycin 1.5 g IV, 12-hourly (adjust initial dosage

    for renal function and monitor blood concentrations,

    see Therapeutic Guidelines Edition 14, appendix 2.3;

    slow infusion required).

    Patients with an immediate type penicillin-allergy

    Consult supervising Haematologist, Oncologist or

    Infectious Diseases Physician on-call via telephone

    49213000.

    Immediate hypersensitivity is characterised by the

    development of urticaria, angioedema,

    bronchospasm or anaphylaxis (with objectively

    demonstrated hypotension, hypoxia or tryptase

    elevation) within one to two hours of drugadministration.

    REFERENCES

    Blood culture collection procedure (CEC)

    Clinical Excellence Commission, Adult Sepsis Pathway

    Therapeutic Guidelines: Antibiotic, Edition 14

    Hunter New England Sepsis Adult First Dose

    Empirical Antibiotic Guideline

    Emergency Department

    management of adults receiving

    chemotherapy with symptoms or

    signs of potential sepsis

    CRITERION

    Any patient who is receiving chemotherapy,

    whether known to be neutropenic or not, who

    presents with fever, chills, rigors or unwell.

    PROCESS

    1. Triage the patient as category 22. Follow theCEC Adult Sepsis Pathway

    (overleaf)

    3. Perform a thorough history andexamination and consider decisions based

    on presumed cause of presentation

    4. Perform investigations (below) PRIOR toadministration of antibiotics. Do NOT delay

    treatment while awaiting results

    5. Commence recommended empiricantibiotic(s) (below). Benchmark for

    administration of antibiotics is less than 1

    hour from triage

    6. Discuss the patient with the supervisingHaematologist or Oncologist as soon as

    possible

    ROUTINE INVESTIGATIONS

    Blood cultures: two sets collected from separate

    peripheral venipunctures (20 mL each set in an

    adult, 3-5mLs in a child). Collection from a pre-

    existing intravascular device should only be done

    as a last resort or after direction by supervising

    Haematologist or Oncologist and must follow

    correct aseptic practice.

    FBC, calcium, electrolytes and LFTs

    Mid-stream urine

    http://proxy9.use.hcn.com.au/tgc/abg/7971.htmhttp://www.cec.health.nsw.gov.au/__documents/programs/sepsis/cec-sepsis-program_adult-blood-culture-sampling-guide_v2-2012.pdfhttp://www.cec.health.nsw.gov.au/__documents/programs/sepsis/cec-sepsis-program_adult-blood-culture-sampling-guide_v2-2012.pdfhttp://www.cec.health.nsw.gov.au/__documents/programs/sepsis/sepsis_pathway_final_3_may_2011_adult.pdfhttp://www.cec.health.nsw.gov.au/__documents/programs/sepsis/sepsis_pathway_final_3_may_2011_adult.pdfhttp://etg.hcn.com.au/http://etg.hcn.com.au/http://intranet.hne.health.nsw.gov.au/__data/assets/pdf_file/0010/67744/HNELHD_CG_12_16_Sepsis_First_Dose.pdfhttp://intranet.hne.health.nsw.gov.au/__data/assets/pdf_file/0010/67744/HNELHD_CG_12_16_Sepsis_First_Dose.pdfhttp://intranet.hne.health.nsw.gov.au/__data/assets/pdf_file/0010/67744/HNELHD_CG_12_16_Sepsis_First_Dose.pdfhttp://www.cec.health.nsw.gov.au/__documents/programs/sepsis/sepsis_pathway_final_3_may_2011_adult.pdfhttp://www.cec.health.nsw.gov.au/__documents/programs/sepsis/sepsis_pathway_final_3_may_2011_adult.pdfhttp://www.cec.health.nsw.gov.au/__documents/programs/sepsis/sepsis_pathway_final_3_may_2011_adult.pdfhttp://www.cec.health.nsw.gov.au/__documents/programs/sepsis/sepsis_pathway_final_3_may_2011_adult.pdfhttp://intranet.hne.health.nsw.gov.au/__data/assets/pdf_file/0010/67744/HNELHD_CG_12_16_Sepsis_First_Dose.pdfhttp://intranet.hne.health.nsw.gov.au/__data/assets/pdf_file/0010/67744/HNELHD_CG_12_16_Sepsis_First_Dose.pdfhttp://etg.hcn.com.au/http://www.cec.health.nsw.gov.au/__documents/programs/sepsis/sepsis_pathway_final_3_may_2011_adult.pdfhttp://www.cec.health.nsw.gov.au/__documents/programs/sepsis/cec-sepsis-program_adult-blood-culture-sampling-guide_v2-2012.pdfhttp://proxy9.use.hcn.com.au/tgc/abg/7971.htm
  • 7/30/2019 @ HNELHD CG 12 16 Sepsis Fact Sheet

    2/2

    CEC Adult Sepsis Pathway- assessment section(see full version for resuscitation guideline)